Javelin Pharmaceuticals to Host 2006 Analyst and Institutional Investor Day.CAMBRIDGE, Mass. -- Javelin Pharmaceuticals, Inc. (Amex: JAV JAV Javanese JAV Japanese Adult Video JAV Ilulissat, Greenland (Airport Code) JAV Jeanne d'Arc de Vaugirard (Paris) JAV Journey Adventure Vehicle JAV Java Applet Viewer JAV Java Alignment Viewer - News) today announced that it will be hosting its 2006 analyst and institutional investor Institutional Investor A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions. day in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , Wednesday, December 6, 2006 from 3-6 p.m. Eastern Standard Time at the InterContinental Barclay New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of at 111 East 48th Street. "Javelin is excited to host its first analyst day in New York City," stated Dr. Daniel Carr, Javelin's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and CMO CMO See: Collateralized mortgage obligation CMO See collateralized mortgage obligation (CMO). . "We are pleased to have Drs. Gharibo and Staats, two distinguished academic thought leaders, who will be joining us to provide an overview of pain treatment today, focusing upon acute, moderate to severe pain. My colleagues and I look forward to updating analysts, shareholders, and prospective institutional investors on our significant progress in 2006 and to highlight goals for 2007, including the anticipated launch of Dyloject." The invitation-only event will be webcast live commencing at 3 p.m. Eastern Time. To access the live audio webcast for this conference, please log onto Javelin Pharmaceuticals, Inc. website at http://ir.javelinpharmaceuticals.com/events.cfm approximately 10 minutes prior to the presentation in order to register and download any necessary software. The event will be archived and available for replay on the Company's website. The program will be as follows: Introduction Fred H. Mermelstein, PhD President & Founder, Javelin Pharmaceuticals, Inc. Acute Pain - Present & Future Christopher Gharibo, MD Director of Pain Medicine, Department of Anesthesiology New York University Medical Center Intranasal Drug Delivery - a Paradigm Shift Michael T. Sheckler, MBA VP Business Development, Javelin Pharmaceuticals, Inc. Rylomine(TM), Controlled Substances & Lessons from Vioxx & OxyContin Curtis Wright IV, MD, MPH Executive VP, Risk Management & Regulatory Affairs, Javelin Pharmaceuticals, Inc. Former Acting Director, Division of Anesthetics, Analgesics, and Substance Abuse; United States Food and Drug Administration Breakthrough Pain, Opioid Resistance & Intranasal Ketamine (PMI-150) Daniel B. Carr, MD, DABPM CEO & CMO, Javelin Pharmaceuticals, Inc. Adjunct Professor of Anesthesiology and Medicine Tufts University School of Medicine, Boston NSAIDs & Dyloject(TM)- the Latest from AHRQ, FDA & EMEA Robert F. Colucci, PharmD, FCCM, FCP Global Director, Dyloject Program, Javelin Pharmaceuticals, Inc. Dyloject(TM) in Europe in 2007 - Commercial Prospects Mark Matthews VP Commercial Affairs, Javelin Pharmaceuticals, Inc. Closing Discussion Filling the Gaps in Pain Management Peter Staats, MD Adjunct Associate Professor Departments of Anesthesiology & Oncology Johns Hopkins University School of Medicine Baltimore, MD Moderated Panel : Questions & Answers About Javelin With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has two drug candidates in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA clinical development and one in late Phase II. One of these Phase III drug candidates, Dyloject, is currently under review for Marketing Authorization Application (MAA MAA abbr. macroaggregated albumin ) approval in Europe. Previous clinical trials have demonstrated its safety and rapid onset of action onset of action Pharmacology The length of time needed for a medicine to become effective. See Therapeutic drug monitoring. . For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com or contact us directly. Forward Looking Statement This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. JAV-G |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion